H.C. Wainwright assumed coverage of Genfit (GNFT) with a Buy rating and $9 price target The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT: